Protalix BioTherapeutics (PLX) Assets Average (2011 - 2026)
Protalix BioTherapeutics (PLX) posted quarterly Assets Average of $92.3 million for Q1 2026, up 25.37% year-over-year from $73.7 million in Q1 2025, and up 12.19% quarter-over-quarter from $82.3 million in Q4 2025.
Protalix BioTherapeutics (PLX) Assets Average (2011 - 2026) Analysis & Trends
Protalix BioTherapeutics' Assets Average history runs 15 years deep, the most recent figure standing at $92.3 million for Q1 2026.
- In Q1 2026, Assets Average rose 25.37% year-over-year to $92.3 million; the TTM figure through Mar 2026 stood at $92.3 million (up 25.37% YoY), while the FY2025 annual figure was $77.9 million, down 1.32% from the prior year.
- Assets Average for Q1 2026 stood at $92.3 million, up from $82.3 million in the prior quarter.
- The five-year high for Assets Average was $92.3 million in Q1 2026, with the low at $56.2 million in Q4 2022.
- The 5-year median for Assets Average is $76.6 million (2024), against an average of $75.9 million.
- The sharpest annual moves came in 2022 and 2023: Assets Average sank 38.85% in 2022, then jumped 52.9% in 2023.
- Protalix BioTherapeutics' Assets Average stood at $56.2 million in 2022, then surged by 52.9% to $86.0 million in 2023, then slipped by 21.52% to $67.5 million in 2024, then gained by 21.95% to $82.3 million in 2025, then rose by 12.19% to $92.3 million in 2026.
- Business Quant data shows PLX's Assets Average at $92.3 million in Q1 2026, $82.3 million in Q4 2025, and $80.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.90 Bn | 131.05 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 86.10 Bn | 78.11 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 65.56 Bn | 60.37 Bn | 1.37 Bn | - |
| 4 | Moderna | 55.82 Bn | 50.68 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 42.14 Bn | 37.04 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - | 19.82 Bn |
| 10 | Protalix BioTherapeutics | 188.37 Mn | 147.71 Mn | 12.13 Mn | 106.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 106.34 Mn |
| Mar 31, 2026 | 92.34 Mn |
| Dec 31, 2025 | 82.31 Mn |
| Sep 30, 2025 | 80.38 Mn |
| Jun 30, 2025 | 76.19 Mn |
| Mar 31, 2025 | 73.65 Mn |
| Dec 31, 2024 | 67.49 Mn |
| Sep 30, 2024 | 76.55 Mn |
| Jun 30, 2024 | 90.68 Mn |
| Mar 31, 2024 | 87.13 Mn |
| Dec 31, 2023 | 86.00 Mn |
| Sep 30, 2023 | 87.99 Mn |
| Jun 30, 2023 | 77.49 Mn |
| Mar 31, 2023 | 61.17 Mn |
| Dec 31, 2022 | 56.25 Mn |
| Sep 30, 2022 | 58.67 Mn |
| Jun 30, 2022 | 64.52 Mn |
| Mar 31, 2022 | 71.03 Mn |
| Dec 31, 2021 | 78.57 Mn |
| Sep 30, 2021 | 95.84 Mn |